文献速递肾移植肾小球疾病

补体因子H和I突变致C3肾小球肾炎: deceased供肾移植后快速复发且依库珠单抗有效治疗

C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

本文报道一个携带补体因子H和I致病等位基因家系中唯一同时携带两种突变的成员发生C3肾小球肾炎, deceased供肾移植后因 prolonged delayed graft function、大量蛋白尿和孤立性C3低补体血症行移植肾活检确诊早期复发,依库珠单抗治疗获显著临床反应。

要点

  • CFH和CFI双突变家系成员发生C3GN,移植后早期复发。
  • deceased供肾移植 prolonged delayed graft function、大量蛋白尿及C3低补体血症提示复发。
  • 依库珠单抗治疗后移植肾功能恢复、蛋白尿完全缓解。

核心结论

  • CFH和CFI双突变患者 deceased供肾移植后出现C3GN早期复发,依库珠单抗治疗获显著临床反应。

研究设计与样本

  • 病例报告:一个携带CFH和CFI致病等位基因家系中唯一同时携带两种突变的成员接受 deceased供肾移植。

主要发现

  • 该患者 deceased供肾移植后出现 prolonged delayed graft function、大量蛋白尿和孤立性C3低补体血症,移植肾活检确诊复发性C3GN。
  • 依库珠单抗治疗后移植肾功能恢复、蛋白尿完全缓解。

临床怎么用

  • 对已知补体调节基因突变的C3GN移植受者,移植后需警惕早期复发并考虑依库珠单抗治疗。

局限性

  • 单例病例报告,结论不能外推至所有C3GN患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: C3 glomerulonephritis (C3GN) is caused by alternate complement pathway over-activation. It frequently progresses to end-stage renal disease, recurs in two-thirds of transplants and in half of these cases progresses to allograft loss. There is currently no proven treatment for C3GN. CASE PRESENTATION: We describe a family segregating pathogenic alleles of complement factor H and I (CFH and CFI). The only member carrying both mutations developed C3GN. Prolonged delayed graft function after deceased donor transplantation, heavy proteinuria and isolated C3 hypocomplementemia prompted an allograft biopsy confirming diagnosis of recurrent C3GN. DISCUSSION: This is the first report of early recurrence of C3GN in an allograft in a patient with known mutations in complement regulatory genes and no preexisting para-proteinemia. Complement activation resulting from ischemia-reperfusion injury from prolonged cold ischemia time unabated in the setting of deficiency of two major complement regulators likely led to the early and severe recurrence. In atypical hemolytic uremic syndrome, the terminal complement cascade activation in the sentinel event initiating endothelial injury; blockade at the level of C5 convertase with eculizumab is uniformly highly effective in management. C3 glomerulopathies (C3GN and dense deposit disease) are a more complex and heterogeneous group. The relative degree of dysregulation at the levels of C3 and C5 convertases and therefore response to eculizumab varies among patients. In our patient, the clinical response to eculizumab was dramatic with recovery of allograft function and complete resolution of proteinuria. We review all cases of recurrent C3 glomerulopathy treated with eculizumab and discuss how complement biomarkers may aid in predicting response to therapy.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Garg N, Zhang Y, Nicholson-Weller A, et al. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab. Nephrol Dial Transplant. 2018. PMID: 29370420. doi:10.1093/ndt/gfx369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。